Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 1.11.2024B.Braun Melsungen AG (BME)76566Metronidazol B. Braun 5 mg/ml (sol inf 20x100 ml/500 mg (fľ. PE))1.11.2024O
 31.10.2024Teva B.V. (TEV-NL-4)91364Gabapentin-Teva 100 mg (cps dur 100x100 mg (blis.PVC/PVDC/Al))21.10.2024O
 31.10.2024Engelhard Arzneimittel GmbH & CoKG (ENL)7402BPROSPAN (sir 1x200 ml (fľ.skl.hnedá))4.11.2024O
 31.10.2024Haleon Czech Republic s.r.o. (HLE)2596EPanadol Migréna (tbl flm 20x250 mg/250 mg/65 mg (blis.PVC/PCTFE/PVC-transp. s bezpeč.fóliou Al/PET))30.10.2024R
 31.10.2024Teva B.V. (TEV-NL-4)90128AZILECT 1 mg tablety (tbl 100x1 mg (blis.Al/Al))30.10.2024O
 31.10.2024GlaxoSmithKline Biologicals S.A. (GAG)01399Infanrix Polio (sus iru 10x0,5 ml (striek.inj.napl.skl.+10 ihiel))28.10.2024O
 31.10.2024medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)4596EMetoject PEN 12,5 mg injekčný roztok naplnený v injekčnom pere (sol ira 6x0,25 ml/12,5 mg (pero napl. YpsoMate))4.11.2024U
 31.10.2024medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)4684EMetoject PEN 7,5 mg injekčný roztok naplnený v injekčnom pere (sol ira 6x0,15 ml/7,5 mg (pero napl. YpsoMate))4.11.2024U
 31.10.2024medac Gesellschaft für klinische Spezialpräparate m.b.H. (MED-2)4618EMetoject PEN 17,5 mg injekčný roztok naplnený v injekčnom pere (sol ira 6x0,35 ml/17,5 mg (pero napl. YpsoMate))4.11.2024U
 31.10.2024GlaxoSmithKline Biologicals S.A. (GAG)45411Boostrix Polio (sus iru 10x0,5 ml (striek.skl.napl.s ihlou))28.10.2024O
 31.10.2024GlaxoSmithKline Trading Services Limited (GAG-IRL-3)6360CAugmentin DUO s príchuťou miešaného ovocia (plu por 1x70 ml (fľ.skl.))28.10.2024O
 31.10.2024Fresenius Kabi s.r.o. (FRK-CZ-3)81318Isolyte (sol inf 10x500 ml (fľaša LDPE - KabiPac))31.10.2024R
 31.10.2024Fresenius Kabi s.r.o. (FRK-CZ-3)1287CBendamustine Kabi 2,5 mg/ml (plc ifc 1x25 mg (liek.inj.skl.))18.11.2024R
 31.10.2024Fresenius Kabi s.r.o. (FRK-CZ-3)0982BLevobupivacaine Kabi 5 mg/ml (sol ijf 5x10 ml/50 mg (amp.PP))18.11.2024R
 31.10.2024Fresenius Kabi s.r.o. (FRK-CZ-3)86365Fluconazol Kabi 2 mg/ml (sol inf 10x200 ml/400 mg (fľ.LDPE))31.10.2024R

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)